STOCK TITAN

Immunome (IMNM) Revenue by Year

IMNM NASDAQ

Immunome, Inc. generated $6.9M in revenue in fiscal year 2025. This represents a decrease of 23.2% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $0 in revenue. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Immunome, Inc. has filed alongside them.

FY2025 annual
Revenue $6.9M
YoY -23.2%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

IMNM Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
Revenue$0$6.9M-23.2%$9.0M-35.5%$14.0MN/AN/AN/AN/A

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

IMNM Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$0n/m$0-100.0%$0-100.0%$0-100.0%$0-100.0%$4.0M+69.8%$2.9M+184.4%$2.7M-28.4%$2.9M-18.4%$2.4M-44.5%$1.0M-56.5%$3.8M

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More Immunome, Inc. financials

Frequently Asked Questions

Immunome, Inc. generated $6.9M in revenue in fiscal year 2025.

Immunome, Inc. (IMNM) revenue fell by 23.2% year over year, from $9.0M to $6.9M in fiscal year 2025.

Immunome, Inc. (IMNM) reported $0 in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Immunome, Inc. (IMNM) reported $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what Immunome, Inc. (IMNM) reported on that line in every period on record.